Idenix Pharmaceuticals Prices Public Offering of Common Stock

_{//health-fitness.news-articles.net/content/2011/ .. cals-prices-public-offering-of-common-stock.html}
^{Published in Health and Fitness on Wednesday, November 16th 2011 at 5:47 GMT by Market Wire}  

Idenix Pharmaceuticals Prices Public Offering of Common Stock -- CAMBRIDGE, Mass., Nov. 16, 2011 /PRNewswire/ --

[ ]

My news for Investors

AtLeast one of the check box should be selected You are following news about Follow the latest news about IDIX

CAMBRIDGE, Mass., Nov. 16, 2011 /PRNewswire/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: [ IDIX ]), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the pricing of an underwritten registered public offering of 9,393,416 shares of its common stock at a public offering price of $6.50 per share. All of the shares are being sold by Idenix. The offering is expected to close on November 21, 2011, subject to customary closing conditions.

J.P. Morgan Securities LLC is acting as sole book-running manager and underwriter for the offering.  Idenix has granted the underwriter a 30-day option to purchase up to an additional 1,409,013 shares to cover over-allotments, if any.

The shares will be issued pursuant to a shelf registration statement on Form S-3 previously filed with and declared effective by the Securities and Exchange Commission. Idenix will also file with the Securities and Exchange Commission a prospectus supplement with respect to the offering.

This announcement shall not constitute an offer to sell or the solicitation of an offer to buy any securities of Idenix, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Copies of the prospectus supplement and accompanying prospectus may be obtained, when available, from J.P. Morgan Securities LLC via Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by calling toll-free (866) 803-9204.

MTS Securities, LLC provided financial advisory services to Idenix.

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of infections caused by the hepatitis C virus.

Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Eric Hoffman (617) 224-4485 (investors)

SOURCE Idenix Pharmaceuticals, Inc.

RELATED LINKS
[ http://www.idenix.com ]